Key facts
- Synthekine’s last known valuation is $500.0M (Dec 2022).
- It has raised $288.6M; the latest was Later Stage VC in Oct 2025.
- Notable investors include RA Capital Management, Canaan Partners, Emerson Collective, Deerfield Management, Samsara BioCapital — 13 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 13 names
- ·Watchlist + deal alerts for Synthekine
- ·The full record, as it builds
Funding rounds
No funding rounds for Synthekine are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Synthekine
Developer of engineered cytokine therapeutics designed to facilitate disease-optimized treatments. The company leverages immunological insights to guide targeted protein engineering and generate transformative medicines, enabling the medical community to optimize the treatment of cancer and autoimmune disorders.
- Sector
- Healthcare
- HQ
- Menlo Park, CA, United States
- Founded
- 2018
- Employees
- 70
- Website
- synthekine.com/
- Ownership
- Privately Held (backing)
Synthekine doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Synthekine shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Synthekine in its N-PORT filings yet. We sweep new filings monthly.